Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for AMGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1988. Start Trial.
Date Value
December 31, 2025 9.958B
December 31, 2024 11.49B
December 31, 2023 8.471B
December 31, 2022 9.721B
December 31, 2021 9.261B
December 31, 2020 10.50B
December 31, 2019 9.15B
December 31, 2018 11.30B
December 31, 2017 11.18B
December 31, 2016 10.35B
December 31, 2015 9.731B
December 31, 2014 8.555B
December 31, 2013 6.291B
December 31, 2012 5.882B
December 31, 2011 5.119B
December 31, 2010 5.787B
December 31, 2009 6.336B
December 31, 2008 5.988B
December 31, 2007 5.401B
December 31, 2006 5.389B
Date Value
December 31, 2005 4.911B
December 31, 2004 3.697B
December 31, 2003 3.567B
December 31, 2002 2.249B
December 31, 2001 1.480B
December 31, 2000 1.635B
December 31, 1999 1.075B
December 31, 1998 1.042B
December 31, 1997 902.90M
December 31, 1996 822.60M
December 31, 1995 773.20M
December 31, 1994 531.89M
December 31, 1993 433.01M
December 31, 1992 292.80M
December 31, 1991 219.72M
March 31, 1991
March 31, 1990 18.69M
March 31, 1989 -5.85M
March 31, 1988 6.414M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Gilead Sciences, Inc. 10.02B
Regeneron Pharmaceuticals, Inc. 4.979B
AbbVie, Inc. 19.03B
Biogen, Inc. 2.205B
Vertex Pharmaceuticals, Inc. 3.631B